ProQR Therapeutics (PRQR)
(Real Time Quote from BATS)
$2.03 USD
+0.09 (4.64%)
Updated Apr 29, 2024 12:57 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
PRQR 2.03 +0.09(4.64%)
Will PRQR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PRQR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRQR
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
Is ProQR (PRQR) Stock a Solid Choice Right Now?
PRQR: What are Zacks experts saying now?
Zacks Private Portfolio Services
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Lags Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
Other News for PRQR
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
ProQR Therapeutics Announces Board Nomination and AGM
ProQR Therapeutics nominates Maier to board of directors
ProQR Highlights Upcoming Presentations on Axiomerâ„¢ RNA Editing at ASGCT 27th Annual Meeting
ProQR Achieves Successful Defense of New Challenge to its Axiomerâ„¢ IP Portfolio